Want to see UTHR full AI Analyst Report?
UTHR Stock Chart & Stats
$516.68
-$0.53(-0.10%)
At close: 4:00 PM EDT
$516.68
-$0.53(-0.10%)
Day’s Range― - ―
52-Week Range$409.07 - $609.35
Previous Close$527.94
Volume431.35K
Average Volume (3M)891.35K
Market Cap
$23.76B
Enterprise Value$22.15B
Total Cash (Recent Filing)$2.66B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)18.3
Beta0.53
Next Earnings
Nov 04, 2026EPS Estimate
6.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)30.23
Shares Outstanding42,890,694
10 Day Avg. Volume850,774
30 Day Avg. Volume891,345
Financial Highlights & Ratios
PEG Ratio1.16
Price to Book (P/B)3.04
Price to Sales (P/S)6.78
P/FCF Ratio20.74
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue7.02
Enterprise Value/Gross Profit8.15
Enterprise Value/Ebitda13.21
Forecast
1Y Price Target
$660.36Price Target Upside27.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)26.63
Revenue Forecast (FY)$3.20B
Bulls Say, Bears Say
Bulls Say
Profitability And Cash GenerationVery high margins and substantial cash generation provide durable funding for clinical development, commercial expansion and capital returns. Strong cash conversion also reduces dependence on external financing, allowing United Therapeutics to pursue its pipeline while retaining financial flexibility.
Conservative Balance SheetEssentially debt-free finances give United Therapeutics resilience through commercial volatility and capacity to fund research, launches and organ-platform investments internally. The substantial equity base and strong returns on equity reinforce the company’s ability to compound without balance-sheet strain.
Pipeline And Regulatory ExpansionMultiple late-stage programs and regulatory filings could broaden United Therapeutics’ addressable markets beyond established PAH products. Positive Phase III results, near-complete PPF enrollment and planned device filings create several opportunities for durable product growth over the next two years.
Bears Say
Sharp TTM Revenue DeclineThe sharp TTM revenue contraction interrupts the company’s prior multi-year expansion and raises questions about the reliability of near-term growth. Even with high absolute margins, continued weakness could reduce operating leverage and constrain the pace at which pipeline investments translate into earnings.
Tyvaso Competitive PressureTyvaso is a major revenue contributor, so competition in inhaled prostacyclin can affect adoption, market share and commercial growth for a core franchise. Patient-level momentum may not fully offset competitive erosion if alternatives gain prescribing traction in relevant indications.
Revenue Forecast And Regulatory UncertaintyWith 2026 guidance withheld and launch timing dependent on regulatory review, revenue visibility is lower during the next several quarters. Delayed approvals or slower commercialization could postpone expected pipeline contributions and make planning for sales investment and cash deployment less predictable.
United Therapeutics News
UTHR FAQ
What was United Therapeutics’s price range in the past 12 months?
United Therapeutics lowest stock price was $409.07 and its highest was $609.35 in the past 12 months.
What is United Therapeutics’s market cap?
United Therapeutics’s market cap is $23.76B.
When is United Therapeutics’s upcoming earnings report date?
United Therapeutics’s upcoming earnings report date is Nov 04, 2026 which is in 14 days.
How were United Therapeutics’s earnings last quarter?
United Therapeutics released its earnings results on Aug 05, 2026. The company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.862 by $0.408.
Is United Therapeutics overvalued?
According to Wall Street analysts United Therapeutics’s price is currently Undervalued.
Does United Therapeutics pay dividends?
United Therapeutics does not currently pay dividends.
What is United Therapeutics’s EPS estimate?
United Therapeutics’s EPS estimate is 6.03.
How many shares outstanding does United Therapeutics have?
United Therapeutics has 42,890,694 shares outstanding.
What happened to United Therapeutics’s price movement after its last earnings report?
United Therapeutics reported an EPS of $7.27 in its last earnings report, beating expectations of $6.862. Following the earnings report the stock price went up 0.064%.
Which hedge fund is a major shareholder of United Therapeutics?
Currently, no hedge funds are holding shares in UTHR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
United Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$660.36 (27.81% Upside)
$660.36 (27.81% Upside)
Blogger Sentiment
Neutral
UTHR Sentiment 55%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 45.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.00%
12-Months-Change
Fundamentals
Return on Equity
20.18%
Trailing 12-Months
Asset Growth
-8.70%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
United Therapeutics
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
UTHR Company Deck
UTHR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced significant near-term commercial challenges with very strong clinical and pipeline momentum. Short-term results (Q2 revenue) came in below expectations and Tyvaso faces competitive pressure, creating uncertainty for 2026 revenue. Offsetting this are multiple highly positive Phase III outcomes, major regulatory filings (ralinepag NDA and Tyvaso IPF sNDA), planned additional filings (DPI and SMI), near-complete enrollment for a large PPF trial, aggressive commercial investments (≈100% sales force expansion), and progress across a differentiated xenotransplantation/organ pipeline. Given the material potential of the recent clinical wins and the company’s execution initiatives that could drive meaningful upside in 2027 and beyond, the positives outweigh the near-term lowlights.View all UTHR earnings summariesUTHR Revenue Breakdown
53.01% Tyvaso
21.26% Remodulin
15.44% Orenitram
8.55% Unituxin
1.75% Other
UTHR Stock 12 Month Forecast
Average Price Target
$660.36
▲(27.81% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Insmed
―
Jazz Pharmaceuticals
―
BridgeBio Pharma
―
Ownership Overview
1.95% Insiders
23.10% Mutual Funds
1.26% Other Institutional Investors
41.52% Public Companies and
Individual Investors